Objective Daptomycin, a cyclic lipopeptide that exhibits rapid, concentration-dependent bactericidal activity in vitro against a broad spectrum of Gram-positive pathogens, has now, since 2003, been ...
An antibiotic used to treat infective diarrhea could be an effective drug for a type of inflammatory bowel disease, a new ...
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
A team of researchers from the Keck School of Medicine of USC has unlocked the details of a cellular pathway that triggers ...
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.
Hosted on MSN14h
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback